Table 5 Distribution of ESBLs genes among three groups of ESBL-producing strains
ESBLs genes | Total | Nosocomial | HCA | CA | P-value | ||
|---|---|---|---|---|---|---|---|
(n = 131) | (n = 40) | (n = 70) | (n = 21) | HCA versus | CA versus | CA versus | |
Nosocomial | Nosocomial | HCA | |||||
blaSHV | 120 (91.6%) | 34 (85.0%) | 67 (95.7%) | 19 (90.5%) | 0.070 | 0.703 | 0.326 |
blaTEM | 85 (64.9%) | 25 (62.5%) | 45 (64.3%) | 15 (71.4%) | 0.851 | 0.486 | 0.545 |
blaOXA-1-like | 6 (4.6%) | 0 (0.0%) | 5 (7.1%) | 1 (4.8%) | 0.157 | 0.344 | 1.000 |
blaCTX-M-group | 123 (93.9%) | 39 (97.5%) | 65 (92.9%) | 19 (90.5%) | 0.414 | 0.27 | 0.66 |
blaCTX-M-1-group | 55 (42.0%) | 10 (25.0%) | 31 (44.3%) | 14 (66.7%) | 0.044 | 0.002 | 0.072 |
blaCTX-M-9-group | 68 (51.9%) | 26 (65.0%) | 36 (51.4%) | 6 (28.6%) | 0.167 | 0.007 | 0.065 |
blaSHV and blaCTX-M-1-group | 51 (38.9%) | 8 (20.0%) | 30 (42.9%) | 13 (61.9%) | 0.015 | 0.001 | 0.125 |
blaSHV and blaCTX-M-9-group | 61 (46.6%) | 22 (55.0%) | 34 (48.6%) | 5 (23.8%) | 0.516 | 0.020 | 0.044 |
blaTEM and blaCTX-M-1-group | 42 (32.1%) | 9 (22.5%) | 23 (32.9%) | 10 (47.6%) | 0.250 | 0.440 | 0.217 |
blaTEM and blaCTX-M-9-group | 40 (30.5%) | 15 (37.5%) | 21 (30.0%) | 4 (19.1%) | 0.420 | 0.139 | 0.324 |
blaCTX-M-9-group and blaCTX-M-1-group | 8 (6.1%) | 2 (5.0%) | 5 (7.1%) | 1 (4.8%) | – | – | – |
blaSHV, blaTEM and blaCTX-M-9-group | 36 (27.5%) | 13 (32.5%) | 20 (28.6%) | 3 (14.3%) | 0.665 | 0.124 | 0.186 |
blaSHV, blaTEM and blaCTX-M-1-group | 38 (29.0%) | 7 (17.5%) | 22 (31.4%) | 9 (42.9%) | 0.111 | 0.032 | 0.332 |
blaSHV, blaCTX-M-9-group and blaCTX-M-1-group | 8 (6.1%) | 2 (5.0%) | 5 (7.1%) | 1 (4.8%) | – | – | – |
blaTEM, blaCTX-M-9-group and blaCTX-M-1-group | 6 (4.6%) | 2 (5.0%) | 3 (4.3%) | 1 (4.8%) | – | – | – |
blaSHV, blaTEM, blaCTX-M-9-group and blaCTX-M-1-group | 6 (4.6%) | 2 (5.0%) | 3 (4.3%) | 1 (4.8%) | – | – | – |